Batard T, Weyer A, Laroze A, Ickovic M R, David B, Peltre G, Basuyaux B
Laboratoire Français du Fractionnement et des Biotechnologies (LFB), Les Ulis, France.
Clin Exp Allergy. 1996 Nov;26(11):1308-15.
Blocking antibodies are defined as antibodies that compete with IgE for binding to allergens due to their specificity for those allergens. Thus, they may inhibit allergen-induced basophil and mast cell IgE-dependent mediator release both in vivo and in vitro.
The present study was designed to evaluate the ability of antibodies isolated from human plasma samples on a Dactylis glomerata (Cocksfoot) pollen affinity-column to inhibit the Dactylis pollen-induced histamine release from human basophils (BHR) in vitro.
Antibodies from Ig pools containing either high or low IgG4 anti-Dactylis pollen were purified on a Dactylis pollen affinity-column and then separated on an antihuman IgE column. Obtained Ig fractions were incubated for 30 min with Dactylis pollen allergens prior to incubation with basophils from Dactylis pollen-allergic donors. Cell supernatants were assessed for histamine content and the inhibition of BHR was calculated.
Unlike control non-isolated Igs, the antibodies isolated on the Dactylis pollen column were able to inhibit efficiently and in a dose-dependent manner Dactylis pollen-induced BHR. The inhibitory activity was increased in isolated antibody samples that had high IgG4 levels. Antibodies isolated on the Dactylis pollen column, however, consisted not only of true allergen-specific (potentially blocking) antibodies but also of autoanti-IgE binding to allergen-specific IgE and mistaken for allergen-specific antibodies thus opening to question the involvement of the true allergen-specific antibodies in the BHR-inhibitory activity. Unlike the true allergen-specific antibodies, the autoanti-IgE were retained on and eluted from the anti-IgE column. Results showed that both the autoanti-IgE-depleted and the autoanti-IgE-containing fractions accounted for the inhibition observed with the related non-depleted sample that had been isolated on the Dactylis pollen column.
For the first time, the true blocking activity of allergen-specific antibodies is demonstrated, that is, in the absence of the autoanti-IgE which can also inhibit BHR.
封闭抗体是指因其对过敏原具有特异性而与IgE竞争结合过敏原的抗体。因此,它们可能在体内和体外抑制过敏原诱导的嗜碱性粒细胞和肥大细胞IgE依赖性介质释放。
本研究旨在评估从人血浆样本中分离得到的、在鸭茅花粉亲和柱上纯化的抗体在体外抑制鸭茅花粉诱导的人嗜碱性粒细胞组胺释放(BHR)的能力。
含有高或低IgG4抗鸭茅花粉的Ig池中的抗体在鸭茅花粉亲和柱上纯化,然后在抗人IgE柱上分离。获得的Ig组分在与来自鸭茅花粉过敏供体的嗜碱性粒细胞孵育之前,先与鸭茅花粉过敏原孵育30分钟。评估细胞上清液中的组胺含量,并计算对BHR的抑制率。
与对照未分离的Ig不同,在鸭茅花粉柱上分离的抗体能够有效且呈剂量依赖性地抑制鸭茅花粉诱导的BHR。在IgG4水平高的分离抗体样本中,抑制活性增强。然而,在鸭茅花粉柱上分离的抗体不仅包括真正的过敏原特异性(可能具有封闭作用)抗体,还包括与过敏原特异性IgE结合并被误认为是过敏原特异性抗体的自身抗IgE,因此真正的过敏原特异性抗体在BHR抑制活性中的作用受到质疑。与真正的过敏原特异性抗体不同,自身抗IgE保留在抗IgE柱上并从该柱上洗脱。结果表明,去除自身抗IgE的组分和含有自身抗IgE的组分都对在鸭茅花粉柱上分离的相关未去除样本所观察到的抑制作用有贡献。
首次证明了过敏原特异性抗体的真正封闭活性,即在不存在也能抑制BHR的自身抗IgE的情况下的活性。